Azole Antifungals Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Azole Antifungals DMPK and Bioanalytical Services

Azole antifungal bioanalysis is shaped by enzyme interaction, metabolite route, and DDI context. Fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole can require different LC-MS/MS strategies for parent exposure, CYP- or UGT-linked metabolism, P-gp relevance, and interaction-sensitive study designs.

Creative Proteomics develops azole-focused DMPK workflows covering parent-drug quantification, microsome and hepatocyte bioanalysis, MetID, CYP / UGT metabolism support, DDI-oriented exposure comparison, in vivo sample analysis, and custom multi-azole panel development.

Browse Azole Antifungal Drug Index Request Custom Azole Method Support

CYP / UGT routesSeparate CYP3A4, CYP2C19, and UGT1A4-linked workflows instead of treating all azoles as one metabolism class.

DDI-sensitive exposureSupport inhibitor, strong inhibitor, substrate, and P-gp-associated study contexts with fit-for-purpose bioanalysis.

Panel-ready selectivityBuild LC-MS/MS methods for multiple azoles with different metabolism routes, matrices, and concentration windows.

Azole Antifungal Workflow Risks DMPK Strategy Map

🧬

Enzyme-defined study routeCYP3A4, CYP2C19, and UGT1A4 tags determine whether the method is Phase I, Phase II, or DDI-oriented.

🔁

Inhibition and DDI contextFluconazole and itraconazole require exposure data that can support interaction-aware research interpretation.

🚪

P-gp-associated exposureItraconazole and posaconazole may require transporter-aware matrix and panel planning.

🧪

MetID and panel compatibilityVoriconazole, posaconazole, and isavuconazole need compound-specific metabolite and assay-readout logic.

Azole-specific workflow design.Creative Proteomics aligns enzyme route, DDI role, transporter context, biological matrix, and panel compatibility before LC-MS/MS method development begins.

Azole Antifungal Drug Index

Find the Azole Antifungal Compound Behind the Study

Azole studies often diverge by enzyme route and interaction role. Use the index to separate inhibitor-focused exposure work from CYP-linked MetID, UGT-related Phase II analysis, P-gp-associated context, or in vivo distribution-oriented bioanalysis. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only azole antifungals matching all selected values.

5 entries · Page 1 of 2

Analytical Pain Points

What Drives Assay Failure in Azole Antifungal Studies?

Azole antifungals can fail analytically when the same generic assay is used for compounds with different enzyme routes, DDI roles, transporter context, and metabolite requirements. The key issue is not only detection, but whether the workflow matches the study driver behind each azole.

CYP and UGT Routes Split the Workflow

Itraconazole, voriconazole, isavuconazole, and posaconazole do not share the same metabolism logic. CYP3A4, CYP2C19, and UGT1A4-related questions require different model systems and readouts.

Our responseEnzyme-aware microsome / hepatocyte workflows with parent-metabolite tracking and reporting aligned to Phase I or Phase II objectives.

MetID →

DDI-Relevant Azoles Need Interaction-Aware Reporting

Fluconazole and itraconazole can be studied as inhibitor or strong-inhibitor entries, so parent concentration alone may not support the interaction question.

Our responseDDI-oriented azole workflows combining parent-drug quantification, inhibitor-context interpretation, and compatible co-analyte planning.

DDI Support →

P-gp Context Can Change Panel Planning

Itraconazole and posaconazole introduce P-gp relevance. Matrix selection, calibration range, and multi-analyte compatibility can be affected when transporter context is part of the design.

Our responseTransporter-aware LC-MS/MS planning for azole exposure studies, tissue matrices, and multi-azole panel compatibility.

Transporter Bioanalysis →

MetID Requirements Differ by Compound

Voriconazole, posaconazole, and isavuconazole may all need MetID support, but expected transformation classes and confirmation logic are not identical.

Our responseCompound-specific MetID plans defining sample model, transformation class, MS acquisition approach, and confirmation strategy before analysis.

Metabolite Profiling →

Multi-Azole Panels Need Balanced Selectivity

A multi-azole method may include inhibitors, substrates, Phase I targets, Phase II targets, and P-gp-associated analytes with different analytical behavior.

Our responseCustom LC-MS/MS panels with extraction, chromatography, MRM transitions, internal standards, and matrix-matched calibration optimized at panel level.

Custom Panels →

Focused Service Paths

Four Practical Routes for Azole Antifungal Studies

Azole workflows should be selected according to study objective: parent-drug exposure, CYP / UGT metabolism, DDI and transporter context, or custom multi-azole panel development.

Parent Azole Exposure Profiling

For studies requiring fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole, or related azole concentration data in biological matrices.

Parent azole quantification
Plasma / serum bioanalysis
In vivo sample analysis
Matrix-specific concentration planning

LC-MS/MS Drug Quantification →

CYP / UGT Metabolism and MetID

For Phase I or Phase II transformation studies involving CYP3A4, CYP2C19, UGT1A4, microsome, or hepatocyte workflows.

Voriconazole CYP2C19 / CYP3A4 MetID
Itraconazole and isavuconazole CYP3A4 context
Posaconazole UGT1A4 / Phase II support
Parent-metabolite interpretation

Metabolite Identification →

DDI, Inhibition, and P-gp Context

For inhibitor, strong inhibitor, substrate, or P-gp-associated azole studies where interaction relevance changes the assay logic.

Fluconazole DDI-focused support
Itraconazole strong-inhibitor workflows
P-gp-associated exposure context
Interaction-aware reporting

Drug–Drug Interaction Support →

Custom Multi-Azole Panel Development

For studies involving multiple azoles, parent-metabolite pairs, CYP / UGT comparison, or DDI-oriented panel workflows.

Multi-azole LC-MS/MS panels
Parent and metabolite compatibility
Matrix-matched calibration
Custom MRM and chromatographic selectivity

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Azole Antifungal?

If you are working with a triazole antifungal, CYP-interacting compound, UGT-related azole, P-gp-associated analyte, DDI-sensitive comparison, tissue-distribution study, or complex multi-azole panel, a standard parent-only LC-MS/MS method may not answer the study question.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows by defining the enzyme route, interaction role, transporter context, analyte list, matrix type, expected concentration range, Phase I / Phase II metabolism needs, and panel compatibility before method development begins.

Target azole antifungal

CYP / UGT concern

P-gp context

DDI question

MetID need

Panel requirements